(aR,bS)-rel-Bedaquiline-d6

(αS,βS)-rel-Bedaquiline-d6 is a deuterated analog of bedaquiline, a medication used for the treatment of multidrug-resistant tuberculosis. The deuterium substitution is a common practice in medication development as it increases the stability and bioavailability of the compound. Bedaquiline works by inhibiting the production of ATP, the energy molecule, in the bacteria causing tuberculosis. (αS,βS)-rel-Bedaquiline-d6 has the same mechanism of action as its non-deuterated counterpart. It specifically targets the ATP synthase enzyme, which is essential for the survival of the bacteria. By inhibiting this enzyme, the bacteria are unable to produce the energy required for their survival, leading to their death. The usage of (αS,βS)-rel-Bedaquiline-d6 is similar to that of bedaquiline. It is administered orally as a tablet and is typically used in combination with other antibiotics for the treatment of multidrug-resistant tuberculosis. The recommended dosage and duration of treatment may vary depending on the severity of the infection and the patient's medical history. In terms of chemical information, (αS,βS)-rel-Bedaquiline-d6 has a molecular formula of C32D6H30Cl2N3O2P and a molecular weight of 570.52 g/mol. It is a white to off-white powder that is soluble in organic solvents such as ethanol and methanol. The deuterium substitution is located at the α and β carbon atoms of the cyclohexane ring in the structure of bedaquiline.